Who
Salvia Investment GmbH
10% owner
Company insider
Files Form 4 as: 10% owner, Bambusa Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 1
- Sells
- 0
- Bought
- $6.0M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Nov 2026
- Last trade
- 2 Nov 2026
- Last filed
- 2 Nov 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Nov 2026filed 2 Nov 2026 | BBTX Bambusa TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,769,701 | filing |
| 2 Nov 2026filed 2 Nov 2026 | BBTX Bambusa TherapeuticsBiotechnology | SEC FORM 4 Bought | $6.0M375,000 at $16.00 | filing |
| 2 Nov 2026filed 2 Nov 2026 | BBTX Bambusa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,135,066 at $0.00 | filing |
| 2 Nov 2026filed 2 Nov 2026 | BBTX Bambusa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,473,775 at $0.00 | filing |
| 2 Nov 2026filed 2 Nov 2026 | BBTX Bambusa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —160,860 at $0.00 | filing |
News
Bambusa Therapeutics raises $168.9 million in biotech IPO priced at $16BBTX · 247wallst.com · 30 Oct 2026
0 headlines in the last 90 days name Salvia Investment GmbH; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.